Overview

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Gemcitabine